Onyx Healthcare Inc. (6569) fair value: what the stock is really worth
As of Nov 9, 2026: fair value (intrinsic value) of Onyx Healthcare Inc. stock TWD 33.79, price TWD 81.20, that is 58.4% below the price, quality 62 out of 100. Rating: strongly overvalued. Calculated from audited financials with 24 of our 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 6, 2026.
How to read this chart
60‑month range 67.28 TWD – 215.63 TWD · fair‑value band 29.28 TWD – 42.35 TWD · the 81.20 TWD price screens above the 33.79 TWD fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 6, 2026.
Follow Onyx Healthcare in your weekly email
Every Wednesday you see whether Onyx Healthcare is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Onyx Healthcare Inc., a professional medical IT company, engages in the design, manufacture, and trade of medical computers and peripherals for hospital/clinical IT market in Taiwan, the United States, and internationally.
Show moreShow less
The company offers medical AI computer; medical tablet, power bank, and display; and medical panel and box PC. It also provides ODM/OEM services; smart view medical stations; fan less slim panel PC; medical display; healthcare infotainment; and medical pc and mobile computing cart.
The company was incorporated in 2010 and is based in New Taipei City, Taiwan.
Stock analysis
Onyx Healthcare Inc. (6569) currently trades at 81.20 TWD, while our model-based Fair Value estimate is 33.79 TWD, 58% below the price, so the stock looks overvalued today.
Show more
Valuation
Bull case: the Growth Earnings group reads highest at a median of 43.51 TWD per share, and 1 of the 24 models we run sit above the 81.20 TWD price.
Bear case: the Asset-Based group reads lowest at 5.85 TWD, and 23 of the 24 models stay below the price. Data coverage for this calculation is high.
Scenario range: 29.28 TWD (bear) to 42.35 TWD (bull), the price of 81.20 TWD sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 62/100 (solid quality), in the Healthcare sector.
Weak Growth: Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Onyx Healthcare Inc. reported revenue of 1.3B TWD in FY2025 versus 1.2B TWD in FY2021, a compound +2.2%/yr. Reported net income was 112M TWD in FY2025, compounding −3.2%/yr from FY2021.
Key figures
Market cap 3.5B TWD (≈ $106M) Micro · P/E ratio 17.5 · P/S ratio 2.40 · EPS (TTM) 4.64 TWD · Dividend yield 3.1% · Net margin 12.6% · Return on equity 12.0% · Return on assets (EBIT) 8.5% (5-year average).
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 46 out of 100 (low confidence).
What moves the price
The share trades about 32% below its 52-week high and at its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at 3% fair-value upside, at −58%, 6569 screens richer than that median.
Fair Value models
Bear29.28 TWDFair Value 33.79 TWDBull42.35 TWD
Price 81.20 TWD · Downside -58.4%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2025 figures (about 10 months old). Earnings retained since then (1.84 TWD per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.40/100
Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Revenue growth 1 year
+5.8%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−6.4%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−0.5%
Start year 2020 (pandemic)
Revenue growth 6 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−2.0%
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years), in TWD ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Measured in TWD: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
−6.3%
Earnings growth per share plus dividend.
Earnings per share, growth per year−9.4%
Dividend (yield on the price)3.1%
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.15% → 4%
Growth Forecast
A lot of optimism in the price
The price assumes more growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+14.9%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
After inflation (Taiwan: IMF forecast 1.6% a year to 2030, 1.5% from 2016 to 2025) that is about +13.2% a year for the price.
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Health Information Services · 117 stocks
Beats the industry median on 9/14 measures
Overall it ranks above its industry peers.
Valuation
Quality Score62 · Above median
Fair Value upside−58.4% · Below median
Profitability
Return on equity (12 months)12.0% · Above median
Return on assets5.2% · Above median
Net margin (12 months)12.6% · Top 25%
Operating margin (12 months)3.9% · Below median
Growth and dividend
Revenue growth (quarter YoY)20.1% · Above median
Dividend yield (12 months)3.1% · Above median
Balance sheet
Debt / equity0.07× · Above median
Valuation Multiplesvs Health Information Services median · lower = cheaper
P/E (12 months)17.5× · Cheaper than median
P/B2.22× · Cheaper than median
P/S (12 months)2.40× · Cheaper than median
Price / free cash flow (fiscal year)23.7× · Pricier than median
EV/EBITDA36.6× · Priciest 25%
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 5
FUTURE (revenue growth)100· sector 46
PAST (return on equity)48· sector 10
HEALTH (low debt)96· sector 98
DIVIDEND (yield)62· sector 41
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Onyx Healthcare Inc. Fair Value". https://www.fairvalue-calculator.com/stock/6569
Frequently asked questions
Is Onyx Healthcare Inc. (6569) overvalued or undervalued?
As of Nov 6, 2026, our model estimates a fair value of 33.79 TWD versus a price of 81.20 TWD, about 58% lower (overvalued).
What is the fair value of 6569?
Our model-based fair value for Onyx Healthcare Inc. is 33.79 TWD (as of Nov 6, 2026), built from audited fundamentals. The current price: 81.20 TWD.
What is the quality score of 6569?
Onyx Healthcare Inc. has a Quality Score of 62/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Onyx Healthcare Inc. (6569)?
Our model-based price target is the fair value of 33.79 TWD (as of Nov 6, 2026) from 24 valuation models. Cautious scenario 29.28 TWD, optimistic scenario 42.35 TWD. It is a calculation from audited fundamentals, not an analyst target.
What is the Onyx Healthcare Inc. stock forecast for 2026?
Our models put fair value at 33.79 TWD, about 58% lower versus a price of 81.20 TWD (overvalued). Cautious scenario 29.28 TWD, optimistic scenario 42.35 TWD. The calculation is refreshed regularly with new filings.
What is the revenue of Onyx Healthcare Inc. (6569)?
Onyx Healthcare Inc. reported trailing-twelve-month revenue of about 1.5B TWD (latest available figure, as of Nov 6, 2026).
Does Onyx Healthcare Inc. pay a dividend?
Onyx Healthcare Inc. currently shows a dividend yield of 3.08% relative to its recent price (as of Nov 6, 2026).
How much is the dividend of Onyx Healthcare Inc. (6569) and when is the ex-dividend date?
Onyx Healthcare Inc. pays a dividend of 2.50 TWD per share a year, a dividend yield of 3.1%. The last ex-dividend date was Jun 30, 2026. A dividend has been paid every year since at least 2016. The payout ratio is 53.9% of earnings. Free cash flow covers the dividend 1.38 times. Our assessment: Well covered. A low payout and the dividend is fully funded by free cash flow, a comfortable, sustainable dividend.
What growth is priced into Onyx Healthcare Inc. (6569)?
For today's price to be fair in a discounted-cash-flow model, Onyx Healthcare Inc. would have to grow free cash flow by +14.9 % per year for five years (discount rate 11.8 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew -0.5 % per year. As of Nov 6, 2026.
What discount rate (WACC) does the fair value of 6569 use?
Our models discount Onyx Healthcare Inc. at 11.8 %: a base by market capitalisation (micro), damped by beta 0.28, country premium for Taiwan. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Onyx Healthcare Inc. that is +14.9 % per year for five years, then slowing evenly to 2 % by year ten, using the same discount rate (11.8 %) and the same formula as our fair value.
How much growth has Onyx Healthcare Inc. (6569) delivered so far?
Over the past 5 years revenue at Onyx Healthcare Inc. grew -0.5 % a year. The price currently implies free-cash-flow growth of +14.9 % per year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Onyx Healthcare Inc. (6569) growing?
The median revenue growth in the sector is +6.2 % a year. That is the yardstick for the growth priced into Onyx Healthcare Inc. (+14.9 % per year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Onyx Healthcare Inc. (6569)?
The free-cash-flow yield on the price is 4.65 %: that much free cash flow Onyx Healthcare Inc. produces per unit of market value. When it exceeds the discount rate of our models (11.8 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Onyx Healthcare Inc. (6569)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Onyx Healthcare Inc. it is 33.79 TWD per share (as of Nov 6, 2026), against a price of 81.20 TWD. It is the blended result of 24 valuation models in 8 families (DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings).
Is Onyx Healthcare Inc. stock overvalued or undervalued in 2026?
As of Nov 6, 2026, 6569 trades above its calculated fair value: price 81.20 TWD, fair value 33.79 TWD, a gap of about −58% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 6569?
No. The price is what the market pays today (81.20 TWD); the fair value is what the company's own numbers justify (33.79 TWD). For Onyx Healthcare Inc. the two are 47.41 TWD per share apart. That gap is exactly why we show both numbers side by side.
How much is Onyx Healthcare Inc. worth?
The market values Onyx Healthcare Inc. at about 3.5B TWD (market capitalisation, as of Nov 6, 2026). Per share that is 81.20 TWD; our models calculate a fair value of 33.79 TWD per share.
What do the bullish and bearish scenarios say about 6569?
Our models span a range for Onyx Healthcare Inc.: cautious scenario 29.28 TWD, base 33.79 TWD, optimistic 42.35 TWD per share (as of Nov 6, 2026, price 81.20 TWD). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of 6569?
Onyx Healthcare Inc. trades at a price-to-earnings ratio of 17.5 (as of Nov 6, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of 33.79 TWD is built from several models across several years. Other multiples: P/B 2.2, P/S 2.4, EV/EBITDA 36.6.
How solid is the balance sheet of Onyx Healthcare Inc. (6569)?
Balance-sheet figures for Onyx Healthcare Inc. (as of Nov 6, 2026): return on equity 12.0%, debt of 0.07 per unit of equity. They feed the Quality Score of 62/100, which measures business quality independently of the share price.
How far is 6569 from its 52-week high?
Onyx Healthcare Inc. trades at 81.20 TWD, about 32% below its 52-week high of 119.03 TWD and at the low of 81.20 TWD (as of Nov 9, 2026). Distance from the high says nothing about value: that is what the fair value of 33.79 TWD is for.
Which stocks are comparable to Onyx Healthcare Inc.?
From the same area (Healthcare) we also value Veeva Systems Inc, Pro Medicus Limited, BrightSpring Health Services, Inc, Hinge Health, Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Onyx Healthcare Inc. stock attractive at the current price?
The data as of Nov 6, 2026: price 81.20 TWD, calculated fair value 33.79 TWD (−58%), Quality Score 62/100, from 24 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 6569 calculated?
We run Onyx Healthcare Inc. through 24 models from 8 families: DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of 33.79 TWD builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. Onyx Healthcare Inc. itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Onyx Healthcare Inc. (6569)?
The closing price on Nov 9, 2026 was 81.20 TWD. Our model-based fair value is 33.79 TWD, about 58% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Onyx Healthcare Inc. right now?
The price sits above even our optimistic bull case (42.35 TWD). The favourable scenario is already priced in. Solid but not exceptional quality (62/100) and above fair value, neither a clear bargain nor a standout compounder.
Key figures of Onyx Healthcare Inc.
How large is the market capitalisation of Onyx Healthcare Inc. (6569)?
The market capitalisation of Onyx Healthcare Inc. is 3.5B TWD (≈ $106M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Onyx Healthcare Inc. (6569)?
The price-to-sales ratio of Onyx Healthcare Inc. is 2.40 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Onyx Healthcare Inc. (6569)?
Earnings per share at Onyx Healthcare Inc. are 4.64 TWD (price ÷ EPS = P/E 17.5). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Onyx Healthcare Inc. (6569)?
The dividend yield of Onyx Healthcare Inc. is 3.1% (payout 53.9%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Onyx Healthcare Inc. (6569)?
The net margin of Onyx Healthcare Inc. is 12.6% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Onyx Healthcare Inc. (6569)?
The return on equity (ROE) of Onyx Healthcare Inc. is 12.0% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Onyx Healthcare Inc. (6569)?
On an EBIT basis the return on assets of Onyx Healthcare Inc. is 8.5% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Onyx Healthcare Inc. (6569)?
The operating margin of Onyx Healthcare Inc. is 3.9% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Onyx Healthcare Inc. (6569)?
Revenue at Onyx Healthcare Inc. is growing +20.1% versus a year earlier (3y avg −6.4%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Onyx Healthcare Inc. (6569)?
Earnings per share at Onyx Healthcare Inc. are growing +159% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net cash does Onyx Healthcare Inc. (6569) hold?
Onyx Healthcare Inc. holds more cash than debt, 160M TWD net (fiscal year 2023). The company holds more cash than debt, a safety cushion.
Free · no account needed
Watch Onyx Healthcare Inc. in the live analysis
One click puts Onyx Healthcare Inc. on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Broad data
Nov 6, 2026